By Eric D. Peterson, MD, MPH, FAHA, Committee on Scientific Sessions Program Chair
The second day of Scientific Sessions features more comprehensive programming on the most up-to-date basic, clinical and population science.
Today’s highlights include the Opening Session at 1 p.m. in Main Event I, Hall D. It will feature the AHA presidential address by John J. Warner, MD, and the annual Lewis A. Conner Memorial Lecture by Eric Dishman, director of the National Institutes of Health’s All of Us Research Program.
Today’s events also include the first of seven Late-Breaking Science Sessions over the next four days that cover some of the most important clinical trials in cardiac science. Today’s session, “CABG and EP Peri-procedural Dilemmas,” begins at 3:45 p.m. in Main Event 1, Hall D, featuring results from the TRiCS III, DACAB, PRESERVE, BRUISE CONTROL-2 and ABRIDGE-J trials.
A Sunday afternoon Main Event session, “Curing Atrial Fibrillation: Where to Next?,” will include presentations on screening, interventional therapies and stroke prevention, as well as a unique presentation by a patient living with AF. The session begins at 3:45 p.m. in Ballroom CD, 3rd Level, Main Building.
The AHA’s joint sessions with other domestic and international cardiology societies are always popular. These sessions offer an invaluable opportunity to collaborate and network with multidisciplinary colleagues from the United States and abroad.
Among the 16 joint sessions scheduled Sunday are collaborations with specialty societies such as the Society of Thoracic Surgeons, Heart Rhythm Society, Society for Cardiovascular Pathology and National Lipid Association. Joint programming with our international colleagues includes the Mexican Society of Cardiology, Brazilian Society of Cardiology, Japanese Circulation Society, Iranian Heart Association and the World Heart Federation.
Abstract poster presentations begin today in the Science and Technology Hall, which opens at 11 a.m. in Hall ABC. Poster sessions offer a terrific opportunity to interact with poster presenters, ask questions and learn about some of the most cutting-edge clinical and basic research in cardiac science. Abstract oral presentations begin this afternoon, including 10 Rapid Fire Oral sessions featuring five-minute abstract presentations. An audience Q&A session will follow each presentation.
Also located in the Science and Technology Hall is the AHA Simulation Zone (booth 2149), which features hands-on demonstrations and case-based learning opportunities to test your cardiac knowledge, skills and critical thinking. The Science and Technology Hall also includes more than 200 exhibitor booths, where you can get information on current drugs and devices related to cardiovascular care.
Check the Final Program and the Mobile Meeting Guide for the complete schedule, including the times and locations of today’s sessions, events and activities. And be sure to check the Daily News each day for program highlights and coverage of the hottest science presented this week.
Late-Breaking Science: CABG and EP Peri-procedural Dilemmas LBS.01 | 3:45-5 p.m. Sunday | Main Event I, Hall D, Main Building
|TRiCS III — An International Multicenter Randomized Trial of Transfusion Requirements in Cardiac Surgery||TRiCS III evaluated liberal versus restrictive transfusion strategies in cardiac surgery.|
|DACAB — Efficacy and Safety of Dual Acetylsalicylic Acid Plus Ticagrelor or Ticagrelor Alone Antiplatelet Strategy After Coronary Artery Bypass Surgery at 12 Months: Randomized Multicentre Trial||DACAB evaluated the efficacy and safety of dual ASA plus ticagrelor or ticagrelor alone antiplatelet strategy after CABG at 12 months.|
|PRESERVE — Sodium Bicarbonate and N-Acetylcysteine for the Prevention of Serious Adverse Outcomes Following Angiography||The PRESERVE trial evaluated the efficacy of IV sodium bicarbonate and oral N-acetylcysteine, which are used to prevent contrast-associated acute kidney injury.|
|BRUISE CONTROL-2 — A Randomized Controlled Trial of Continued versus Interrupted Novel Oral Anti-Coagulant at the Time of Device Surgery||Bruise Control-2 compared continued versus interrupted novel oral anti-coagulant therapy at the time of device surgery with respect to clinically significant pocket hematoma, bleeding and thromboembolic events.|
|ABRIDGE-J — Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial||ABRIDGE-J compared the efficacy and safety of minimally interrupted dabigatran as an anticoagulant therapy with that of uninterrupted warfarin for catheter ablation for nonvalvular atrial fibrillation.|